NDAINTRAVENOUSSOLUTION
Approved
Oct 2019
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
FLUORODOPA F18 (fluorodopa f18) by Medica Corp is 12. First approved in 2019.
Drug data last refreshed 13h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FLUORODOPA F18 is a positron emission tomography (PET) imaging agent used to visualize dopaminergic nerve terminal function in the brain. It is decarboxylated to fluorodopamine and accumulated in striatal presynaptic vesicles, enabling detection of dopamine neuron integrity via PET imaging. The agent is indicated for imaging of dopaminergic dysfunction in neurological disorders.
Peak
Product is at peak commercial stage with moderate competitive pressure (30%), likely supporting a focused commercial team managing established market penetration.
Mechanism of Action
12.1 Mechanism of Action In dopaminergic nerve terminals in the brain, Fluorodopa (FDOPA) F 18 is decarboxylated by amino acid decarboxylase to Fluorodopamine (FDA) F 18 and stored in presynaptic vesicles in the brain. The accumulation of F 18 FDA in the striatum is visually detected in the PET…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on FLUORODOPA F18 at Medica Corp? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.